TipRanks (Tue, 6-Jan 6:06 AM ET)
Business Wire (Mon, 22-Dec 6:00 AM ET)
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Business Wire (Mon, 10-Nov 4:30 PM ET)
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
Business Wire (Wed, 5-Nov 7:00 AM ET)
Business Wire (Mon, 3-Nov 7:00 AM ET)
Business Wire (Thu, 30-Oct 7:00 AM ET)
Business Wire (Mon, 6-Oct 4:00 PM ET)
Business Wire (Mon, 6-Oct 7:00 AM ET)
KalVista Boosts Convertible Notes Offering to $125 Million, Eyeing Growth and EKTERLY Launch
Market Chameleon (Thu, 25-Sep 4:50 AM ET)
EKTERLY Gains EU and Swiss Approval: KalVista Sets Stage for First Oral HAE Therapy Launch
Market Chameleon (Fri, 19-Sep 4:33 AM ET)
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Kalvista Pharmaceuticals trades on the NASDAQ stock market under the symbol KALV.
As of January 6, 2026, KALV stock price climbed to $15.75 with 1,013,080 million shares trading.
KALV has a beta of 0.82, meaning it tends to be less sensitive to market movements. KALV has a correlation of 0.06 to the broad based SPY ETF.
KALV has a market cap of $796.10 million. This is considered a Small Cap stock.
Last quarter Kalvista Pharmaceuticals reported $14 million in Revenue and -$.92 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.12.
In the last 3 years, KALV traded as high as $17.30 and as low as $6.26.
The top ETF exchange traded funds that KALV belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
KALV has outperformed the market in the last year with a return of +74.4%, while the SPY ETF gained +18.1%. In the last 3 month period, KALV beat the market returning +32.9%, while SPY returned +3.7%. However, in the most recent 2 weeks KALV has underperformed the stock market by returning -0.6%, while SPY returned +1.0%.
KALV support price is $15.09 and resistance is $16.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KALV shares will trade within this expected range on the day.
